ASI to Open Pharmaceutical Laboratory in Düsseldorf
News Oct 04, 2012
Ashland Specialty Ingredients (ASI) has announced plans to open a new pharmaceutical application laboratory in Düsseldorf, Germany, in December 2012.
“With a location central to major pharmaceutical and nutraceutical customers in the region, this new lab will enable us to offer sizable value and convenience to global multinational companies as we bring on board research projects,” said Dr. Edmont Stoyanov, technical director pharmaceutical, Europe, the Middle East and Africa, ASI.
Dr. Stoyanov continued, “In addition, it will ensure our capability to realize novel ideas and developments quickly and sharpen our R&D profile. Ultimately, this will help strengthen our position as a leading innovator and deepen our relationship with originator companies.”
The new laboratory will be outfitted with the equipment covering all the processes required for classical pharmaceutical formulation and research.
Staffed with experienced pharmaceutical experts, Ashland’s Düsseldorf lab will ensure that Ashland’s customers continue to receive the high level of technical support to which they’ve grown accustomed, and open doors to promising new opportunities.
The new laboratory will be part of Ashland’s global pharmaceutical facilities network, which includes numerous laboratories and research centers worldwide, facilitating technical assistance for drug solubilization, including hot-melt extrusion and spray drying.
“Placing Ashland’s experienced pharmaceutical experts in Düsseldorf will provide the highest level of technical support for customers in areas like granulation, coating and tableting, including direct compression, roller compaction and wet granulation,” added Stoyanov.
Stoyanov continued, “We can offer our European customers quick and detailed support on all tableting issues. The lab location in Germany will accelerate and optimize the cooperation with the R&D departments of our European customers.”
Additionally, the lab will extend its services to host hands-on applications training and technical seminars for up to 20 people at a time.
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018